US Patent

US12071402 — Immunosuppressant formulations

Formulation · Assigned to Novartis AG · Expires 2032-01-05 · 6y remaining

Vulnerability score 61/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a solid phase pharmaceutical composition containing one or more excipients and an immunosuppressant active pharmaceutical ingredient.

USPTO Abstract

The present invention relates to a solid phase pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and an active pharmaceutical ingredient (“API”) which is a compound of formula A1 or A2 or a pharmacologically acceptable salt, solvate or hydrate thereof, wherein the API is not exposed to a basic compound.

Drugs covered by this patent

Patent Metadata

Patent number
US12071402
Jurisdiction
US
Classification
Formulation
Expires
2032-01-05
Drug substance claim
No
Drug product claim
Yes
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.